ENSYSCE BIOSCIENCES, INC. Debt Conversion, Converted Instrument, Amount
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Debt Conversion, Converted Instrument, Amount of $5.80 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-03-30
- 2021-06-30: Debt Conversion, Converted Instrument, Amount 0 month $5.80M; Debt Conversion, Converted Instrument, Amount 6 month $5.80M.
| Period end | Debt Conversion, Converted Instrument, Amount 0 month | Debt Conversion, Converted Instrument, Amount 6 month |
|---|---|---|
| 2021-06-30 | $5.80M 10-K · filed 2023-03-30 | $5.80M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |